References
- Opelz G, Dohler B, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005;5:2725–2731.
- Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal allograft survival. JAMA. 2000;283:633–638.
- Collins AJ, Foley RN, Herzog C, et al. US renal data system 2010 annual data report. Am J Kidney Dis. 2011;57:A8, e1–A8, e526.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
- Chatzikyrkou C, Menne J, Gwinner W, et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens. 2011;29:2283–2294.
- Stevens KK, Patel RK, Clancy M, et al. Angiotensin blockade is associated with early graft dysfunction after live donor renal transplantation. Transplantation. 2010;89:707–709.
- Paoletti E, Cassottana P, Amidone M, et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis. 2007;50:133–142.
- Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant. 2010;25:967–976.
- Paoletti E, Bellino D, Marsano L, et al. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation. 2013;95:889–895.
- Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol. 2013;24:320–327.
- Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. 2007;357:797–805.
- Correa-Costa M, Azevedo H, Amano MT, et al. Transcriptome analysis of renal ischemia/reperfusion injury and its modulation by ischemic pre-conditioning or hemin treatment. PLoS One. 2012;7:e49569.
- Cavaille-Coll M, Bala S, Velidedeoglu E, et al. Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation. Am J Transplant. 2013;13:1134–1148.
- Sulikowski T, Domanski L, Zietek Z, et al. The effect of preservation solutions UW and EC on the expression of renin I, angiotensinogen and angiotensin I-converting enzyme genes in rat kidney. Ann Transplant. 2011;16:108–113.
- Szczech LA, Granger CB, Dasta JF, et al. Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation. 2010;121:2183–2191.
- Drenger B, Fontes ML, Miao Y, et al. Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality. Circulation. 2012;126:261–269.
- Bos EM, Wang R, Snijder PM, et al. Cystathionine γ-lyase protects against renal ischemia/reperfusion by modulating oxidative stress. J Am Soc Nephrol. 2013;24:759–770.
- Mengel M, Chang J, Kayser D, et al. The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am J Transplant. 2011;11:708–718.
- Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens. 2011;20:246–257.
- Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol. 2006;17:3257–3262.
- Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889–899.
- Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant. 2007;7:2350–2360.
- Sever PS, Chang CL, Prescott MF, et al. Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian cardiac outcomes trial (ASCOT). Eur Heart J. 2012;33:2970–2979.
- Giral M, Foucher Y, Dufay A, et al. Pretransplant sensitization against angiotensin II Type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant. 2013;13:2567–2576.
- Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant. 2013;13:2577–2589.